Inovio post-stock split trading starts today


Inovio's (INO) 1-for-4 reverse stock split became effective yesterday at 5 pm. Trading in post-split shares begins today.

From other sites
Comments (6)
  • mexec1
    , contributor
    Comments (79) | Send Message
     
    Thanks for the reminder! I was long at 3.4 and now that it's down more than 30% from there I'm definitely Long INO, I can't wait to see the institutional players pile into this security,
    6 Jun 2014, 07:57 AM Reply Like
  • Montyinfl
    , contributor
    Comments (37) | Send Message
     
    the reverse split is a good short term corporate startegy to get a lift on the stock; long term questionable.
    6 Jun 2014, 08:43 AM Reply Like
  • think big
    , contributor
    Comment (1) | Send Message
     
    up $13 billon in 2007 expected to reach $52 billon by 2016
    6 Jun 2014, 09:08 AM Reply Like
  • tberry1
    , contributor
    Comments (3) | Send Message
     
    I thought there was suppose to be some kind of phase II crucial announcement by now?
    6 Jun 2014, 01:10 PM Reply Like
  • mexec1
    , contributor
    Comments (79) | Send Message
     
    The phase II announcement is due this month which is why I believe INO is being very strategic with the reverse split before the announcement. The stock was not at risk of being dellisted when they approved or executed the split. Now, the price is past the threshold for institutional players to be able to participate once the announcement is made (which I'm hoping will be very positive).
    7 Jun 2014, 08:33 AM Reply Like
  • drniccoli
    , contributor
    Comments (4) | Send Message
     
    Here is an article by a finacial site I believe this is about Inovio
    He is trying to get people to sign up for his newsletter as he lists other companies that he recommended but certain information in this article points to Inovio.

     

    My 7-Month Investigation Has Uncovered a Medical Miracle:
    One small company controls a specific "Universal Vaccine System" that could prevent and treat prostate cancer… breast and cervical cancer… influenza and more…
    Here's why I'm predicting gains of 311% and higher
    Get my newest briefing immediately
    Dear Reader,

     

    Hi, I'm Bill Patalon, Executive Editor of Money Morning.

     

    Bill Patalon
    My 30-year career as an investigative journalist has given me a before-it-happens look into some of the biggest biotech breakthroughs of the last three decades.

     

    In 2007 my inside access to vaccine maker MedImmune enabled me to give my readers a whole series of briefings as the company created FluMist, the world's first needle-free vaccine.

     

    The FluMist launch spurred a $15.2 billion cash buyout and ignited a 60% jump in MedImmune's shares.

     

    In 2012, I uncovered two companies developing breakthrough "Precision Targeted" cancer therapies and recommended them to my subscribers.

     

    Following those recommendations, the first company, Celldex Therapeutics, achieved a peak gain of 628%.

     

    The second, Pharmacyclics, generated a peak return of 403% gains.

     

    And some of my most recent biotech discoveries have given my readers a chance to get in early enough to see peak gains of…

     

    … 222% on Astex Pharmaceuticals…

     

    … 213% on Galapagos NV… and

     

    … 101% on Trius Therapeutics Inc.…

     

    … to name just a few

     

    But as great as all those gains are, I believe they will be dwarfed by what I'm going to share with you today.

     

    I've just wrapped up a 7-month investigation into a company that has developed what I can only call a "universal" vaccine system… one I believe is about to turn the $30 billion vaccine market on its head.

     

    This is a SINGLE vaccine system that could treat and possibly even prevent prostate cancer… cervical cancer… breast cancer… colon cancer… even head, neck, and throat cancers.

     

    Even more astonishing, the exact same universal vaccination system could also treat and possibly even prevent a host of other deadly diseases including… Hepatitis B and C… HIV… Avian Flu… MERS… SARS… Malaria… Ebola… Multiple Sclerosis… and Alzheimer's disease.

     

    In fact, this company's universal vaccination system could even protect you against the flu… not just for a single season, but for almost a decade or more, and possibly forever.

     

    I know all this may seem hard to fathom. But it's all possible because of a breakthrough process that uses circular pieces of synthetic DNA to teach your immune system to recognize and kill tumors, and then to sweep those infected cells from your body.

     

    In this report I'll show you how this unique system works.

     

    But before I do, just imagine what a boon this universal vaccine system would be – not just for our well-being, but for the company that created and owns the technology and that makes it all happen.

     

    After all, by one conservative estimate, Americans spent more than $2.6 billion on flu shots alone. The pediatric vaccine market by itself is forecast to reach $24 billion by 2017.

     

    Add it all up, and the worldwide vaccine market, now $30 billion, will soar to more than $84 billion in less than a decade.

     

    It's a similar story for cancer treatment.

     

    Globally, men will spend $26 billion this year treating prostate cancer. By 2017 that number will nearly double to $50 billion.

     

    Women will spend almost $12 billion treating cervical cancer and $23.2 billion treating breast cancer.

     

    All told the medical costs of cancer care amount to $125 billion.

     

    But it may soon be possible to inoculate yourself against all of those diseases, and more.

     

    That's why MIT Technology Review reported…

     

    "Most of the experts are in agreement. The idea is a very good one… and any company that would make a dent into this would certainly be a winner."
    I admit that when I first heard about this universal vaccine system, I was a skeptic. I couldn't believe that a single vaccine system could prevent and treat so many different cancers… or that a single shot could prevent the flu forever.

     

    So, I pored through more than 120 research documents related to this company's universal vaccine system.

     

    Five studies showed best-in-class results against cervical cancer… 14 studies supported the safety and effectiveness of their universal HIV vaccine… And six trials proved that their method works against influenza…

     

    One study published by the American Association for the Advancement of Science revealed that 100% of subjects who received this company's universal DNA system for HPV cancers showed "robust" immunity with zero side effects… and that 78% also showed robust response when it came to treating the disease.

     

    A peer-reviewed trial in the Journal of Infectious Diseases showed their universal DNA system was seven times better at fighting HIV compared to a conventional treatment.

     

    An astounding 53 studies proved the power of this company's proprietary electroporation delivery system, which is the secret key to this whole medical miracle.

     

    You see, what makes this new universal vaccine system so revolutionary is that it isn't mere medicine.

     

    It's a powerful, patented combination of two medical breakthroughs.

     

    The vaccines are synthesized out of circular pieces of "edited" DNA that teach the body to fight off any disease the DNA has been engineered to tackle – including strains of the disease that haven't even evolved yet.

     

    But clearly the major breakthrough is a patented, hand-held device that can overcome the final obstacle to using DNA in treatments and vaccines.

     

    You see, synthetic DNA has been around since the 1990s. The problem was that until now scientists could never get enough of it into the cells to do much good.

     

    But with this device – an integral part of the universal vaccine system – the DNA gets administered along with a tiny electric pulse lasting a few hundredths of a second. The pulse causes the cells to open up just long enough for a massive amount of DNA to get inside the cell and go to work.

     

    Then, an army of antibodies and "killer T-cells" – swarms of up to 1,000 times more than are released using traditional methods – seeks out and destroys tumors and infected cells.

     

    In more than 1,500 vaccination trials, the procedure has proven to be 100% safe.

     

    This could well be a first in medical history – a new drug and a breakthrough technology brought together to create a whole new class of medicines.

     

    And only one company in the world can offer this exact system.

     

    I recently met with their CEO. When assessing the profit potential of biotech companies for my readers, I make it a standard part of my research and analysis to seek out and interview key executives and scientists. The information you can learn from these insiders can be invaluable.

     

    But I've learned that you have to go into these meetings as a virtual expert. You need to understand the biotechnology – and the biotech market – backwards and forwards.

     

    That way you'll be able to tell whether a CEO or engineer is genuinely giving you valuable information or just feeding you pie-in-the-sky science or marketing spin.

     

    Well, everything this company's CEO shared with me over four hours confirmed for me what I already suspected: Their universal vaccine system – based on synthetic DNA – could soon be the dominant vaccine technology in the world – an $84 billion market.

     

    I've written up all my findings in a free briefing I'd like to send you called Universal Vaccine: The Biotech Breakthrough That Could Shatter The $84 Billion Vaccine Market.

     

    In it you'll discover the name and ticker symbol of this little-known company, details of their patented universal vaccine system, and why the company's share price could climb as much as 331% in a matter of weeks… and much, much more after that.

     

    I'm predicting gains as high as 2,100% in just a few years. That would be enough to turn every $1,000 into $21,000… Every $10,000 into $210,000!

     

    I want you to have this new briefing today, because this universal vaccine system is wending its way through the FDA-approval process. And right now it's in the home stretch. Make no mistake: This opportunity is immense.

     

    In a minute I'll tell you how to get a copy of my briefing delivered immediately to your inbox – for free.

     

    Before I do though, let me show you exactly why I believe this company can be such a tremendous profit play – not at some later date in the future – but right now.

     

    For starters, the CEO shared with me something that almost nobody else knows: This biotech has a very clear and pinpointed strategy to license their breakthrough products to major pharmaceutical firms.

     

    In fact, this company recently inked a partnership with one of the world's largest Big Pharma companies, to develop two parts of its universal vaccine system – one targeting prostate cancer and the other targeting Hepatitis B.

     

    The deal is potentially worth $423 million and represents barely 10% of what this company has available to license.

     

    If it signs several other deals, as I think the company will, its market value could soar as high as $1.6 to $3.8 billion – between three to seven times what it's worth today.

     

    In short, if the scenario I've worked out for you comes to pass, this company's stock price could rocket from 331% to more than 721% virtually overnight.

     

    And here's the kicker…

     

    Those licensing deals don't need FDA approval, so they could come at any time.

     

    I want to stress that my estimates here are pretty conservative, given what this company's products can accomplish, the massive demand in the market, and the fact that their first deal is already done.

     

    Will this stock climb like that? I've seen it happen before.

     

    When I recommended Astex Pharmaceuticals to my readers, the pharmaceutical firm was trading at $2.75. Thanks in part to a breakthrough Leukemia treatment, Astex shares shot up 64% in three months… and as much as 222% in just nine months.

     

    Galena Biopharma had a similar run, peaking at 227% just nine months after I told my readers about the company's NeuVax TM cancer drug candidate.

     

    Remember, the estimates I just gave are for the short term.

     

    Over the long haul, I believe this company's prospects are even better – according to my research, shares could skyrocket as high as 2,133% once this universal vaccine system hits the market.

     

    I realize nothing's ever 100%. These stocks rise and fall based on clinical results, FDA decisions… cash flow needs…

     

    But I've been investigating biotechnology products, drugs and companies for over 30 years. And the evidence shows this is one of those rare but truly remarkable breakthrough opportunities that only a few investors ever get a chance to profit from.

     

    One of those small companies that can rise very quickly and make a dramatic impact on your net worth in a short period of time.

     

    Which is why I want to rush you Universal Vaccine: The Biotech Breakthrough That Could Shatter The $84 Billion Vaccine Market as soon as possible.

     

    HERE'S HOW TO GET YOUR FREE COPY DELIVERED TO
    YOUR INBOX IN A MATTER OF SECONDS
    To claim your free copy of Universal Vaccine: The Biotech Breakthrough That Could Shatter The $84 Billion Vaccine Market, all you have to do is join me in my Private Briefing service.

     

    Private Briefing is a labor of love for me.

     

    ation. There is an article by William Patalon III the title
    8 Jun 2014, 03:44 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs